Last reviewed · How we verify
Nomegestrol Acetate / Estradiol
Nomegestrol acetate and estradiol work together as a hormonal contraceptive by suppressing ovulation through progestin and estrogen activity.
Nomegestrol acetate and estradiol work together as a hormonal contraceptive by suppressing ovulation through progestin and estrogen activity. Used for Contraception in women of reproductive age.
At a glance
| Generic name | Nomegestrol Acetate / Estradiol |
|---|---|
| Sponsor | University of Palermo |
| Drug class | Combined oral contraceptive |
| Target | Progesterone receptor, Estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | FDA-approved |
Mechanism of action
Nomegestrol acetate is a progestin that inhibits the luteinizing hormone (LH) surge necessary for ovulation, while estradiol (a natural estrogen) provides cycle control and endometrial stability. Together, they create a combined oral contraceptive formulation that prevents pregnancy through multiple mechanisms including ovulation suppression, cervical mucus thickening, and endometrial atrophy.
Approved indications
- Contraception in women of reproductive age
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Venous thromboembolism
Key clinical trials
- Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive (PHASE3)
- The Progression From Dysmenorrhoea to Chronic Pelvic Pain
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448) (PHASE3)
- A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012) (PHASE2)
- A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057) (PHASE2)
- The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation (PHASE4)
- The Use of Nomegestrol Acetate/Estradiol in Random Start Rapid Endometrial Preparation (PHASE4)
- Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nomegestrol Acetate / Estradiol CI brief — competitive landscape report
- Nomegestrol Acetate / Estradiol updates RSS · CI watch RSS
- University of Palermo portfolio CI